Roivant Sciences Ltd. – NASDAQ:ROIV

Add to watchlist

$11.9

+0.09

+0.85%

Market open

Closed in about 3 hours

+3.96%

month

+3.96%

quarter

+1.90%

year

Market Cap	8.63B
Enterprise value	4.25B

P/E	-4.02
EV/Sales	94.25
EV/EBITDA	-4.18
Price/Sales	117.48
Price/Book	5.54
PEG ratio	0.60
EPS	-1.26

Revenue	89.87M
EBITDA	-817.36M
Income	-902.38M
Revenue Q/Q	N/A
Revenue Y/Y	N/A

Profit margin	-2316.63%
Oper. margin	-2445.63%
Gross margin	79.01%
EBIT margin	-2445.63%
EBITDA margin	-909.5%

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Roivant Sciences Ltd. Stock Forecast

M Q Y

Last Year

$15.5

Potential upside: 30.25%

Analysts Price target
Financials & Ratios estimates

Roivant Sciences Ltd. (NASDAQ:ROIV): Profit margin
Dec 2021	24.34M	-284.53M	-1168.96%
Mar 2022	9.22M	-291.31M	-3158.55%
Mar 2023	27.37M	-175.42M	-640.79%
Mar 2024	28.93M	-151.11M	-522.35%

Roivant Sciences Ltd. (NASDAQ:ROIV): Debt to assets
Sep 2022	2215534000	701.38M	31.66%
Dec 2022	2202960000	775.82M	35.22%
Mar 2023	2389604000	782.01M	32.73%
Mar 2024	7222482000	773.95M	10.72%

Roivant Sciences Ltd. (NASDAQ:ROIV): Cash Flow
Dec 2021	-268.49M	-6.07M	-8.42M
Mar 2022	-147.46M	-5.70M	1.07M
Mar 2023	-179.08M	113.55M	210.33M
Mar 2024	-108.45M	6.92M	-32.62M

Roivant Sciences Ltd. alternative data

Roivant Sciences Ltd.
Employees

Roivant Sciences Ltd. (NASDAQ:ROIV): Employee count
Sep 2023	904
Oct 2023	904
Nov 2023	904
Dec 2023	904
Jan 2024	904
Feb 2024	904
Mar 2024	904
Apr 2024	904
May 2024	904
Jun 2024	904
Jul 2024	908

Roivant Sciences Ltd.
Hedge Funds Holdings Q1 2023

11.54% -47.32%

of ROIV is owned by hedge funds

76 -33

hedge funds hold ROIV stock

82.30M -329.60M

shares is hold by hedge funds

ROIV hedge funds holdings changes

Roivant Sciences Ltd.
Insider Trading

Roivant Sciences Ltd. (NASDAQ:ROIV): Insider trades (number of shares)
Period	Buy	Sel
Jan 2024	0	6000000
Feb 2024	0	96950
Sep 2024	0	8088257
Oct 2024	0	100000
Nov 2024	0	100000
Dec 2024	0	1388025

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Option	26 Dec 2024	SUKHATME MAYUKH director, officer: Pres&Chief Investment O.. director, officer: Pres&Chief I..	Common Shares	689,495	$3.85	$2,654,556
Sale	26 Dec 2024	SUKHATME MAYUKH director, officer: Pres&Chief Investment O.. director, officer: Pres&Chief I..	Common Shares	689,495	$12.01	$8,280,835
Option	26 Dec 2024	SUKHATME MAYUKH director, officer: Pres&Chief Investment O.. director, officer: Pres&Chief I..	Stock Option (Right to Buy)	689,495	$3.85	$2,654,556
Option	24 Dec 2024	SUKHATME MAYUKH director, officer: Pres&Chief Investment O.. director, officer: Pres&Chief I..	Common Shares	185,946	$3.85	$715,892
Sale	24 Dec 2024	SUKHATME MAYUKH director, officer: Pres&Chief Investment O.. director, officer: Pres&Chief I..	Common Shares	185,946	$12	$2,231,352
Option	24 Dec 2024	SUKHATME MAYUKH director, officer: Pres&Chief Investment O.. director, officer: Pres&Chief I..	Stock Option (Right to Buy)	185,946	$3.85	$715,892
Option	23 Dec 2024	SUKHATME MAYUKH director, officer: Pres&Chief Investment O.. director, officer: Pres&Chief I..	Common Shares	10,796	$3.85	$41,565
Option	23 Dec 2024	SUKHATME MAYUKH director, officer: Pres&Chief Investment O.. director, officer: Pres&Chief I..	Stock Option (Right to Buy)	10,796	$3.85	$41,565
Option	20 Dec 2024	VENKER ERIC officer: President & COO officer: President & COO	Stock Option (Right to Buy)	100,000	$3.85	$385,000
Option	20 Dec 2024	VENKER ERIC officer: President & COO officer: President & COO	Common Shares	100,000	$3.85	$385,000

ROIV insider trading transactions

Roivant Sciences Ltd.
Earnings Call Transcripts

Quarter	Transcript
Q4 2023 30 May 2024	Q4 2023 Earnings Call Transcript
Q3 2023 13 Feb 2024	Q3 2023 Earnings Call Transcript
Q2 2023 13 Nov 2023	Q2 2023 Earnings Call Transcript
Q1 2023 14 Aug 2023	Q1 2023 Earnings Call Transcript

ROIV earnings call transcripts

Roivant Sciences Ltd.
Executives

Insider	Age	Compensation
Dr. Eric Venker M.D., Pharm.D. (1987) Pres & Chief Operating Officer	38	$813,550
Mr. Matthew Gline (1984) Chief Executive Officer & Director	41	$813,550
Mr. Vivek Ramaswamy (1985) Founder & Executive Chairman	40	$511,800

Roivant Sciences Ltd.
Latest News

Wednesday, 4 December 2024
08:30	Roivant Sciences: A Biotech Growth Play With Major Ambitions	seekingalpha.com
Tuesday, 3 December 2024
07:19	Roivant's lung disease drug fails mid-stage trial	reuters.com
Tuesday, 12 November 2024
14:41	Roivant Sciences Ltd. (ROIV) Q2 2024 Earnings Call Transcript	seekingalpha.com
09:35	Roivant Sciences Ltd. (ROIV) Reports Q2 Loss, Misses Revenue Estimates	zacks.com
Tuesday, 29 October 2024
16:35	Roivant to Report Financial Results for the Second Quarter Ended September 30, 2024 and Provide Business Update on Tuesday, November 12, 2024	globenewswire.com
Monday, 28 October 2024
09:25	Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%	globenewswire.com
Tuesday, 22 October 2024
12:31	Roivant Sciences: Good Value, But Near-Term Catalysts Could Bring Volatility	seekingalpha.com
Friday, 7 June 2024
18:26	The 'Undercovered' Dozen From June 1-6	seekingalpha.com
Sunday, 2 June 2024
07:27	Roivant Sciences: Executing On Huge Buyback Program With More To Come	seekingalpha.com
Thursday, 30 May 2024
09:21	Roivant Sciences Ltd. (ROIV) Reports Q4 Loss, Misses Revenue Estimates	zacks.com
07:00	Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provides Business Update	globenewswire.com
Thursday, 16 May 2024
16:05	Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provide Business Update on Thursday, May 30, 2024	globenewswire.com
Tuesday, 7 May 2024
14:04	Biotech Breakthroughs: 7 Stocks Driving the Next Wave in Healthcare	InvestorPlace
Wednesday, 1 May 2024
10:47	3 Healthcare Stocks With the Potential to Triple Your Investment by 2026	InvestorPlace
Sunday, 7 January 2024
13:15	Roivant Sciences: Why Its 'Vant' Biotech Model Is A Buy	Seeking Alpha
Monday, 27 November 2023
12:51	Roivant Sciences unable to determine effectiveness of lupus drug in Phase 2 study	Proactive Investors
08:52	Roivant Sciences shares drop as lupus treatment misses trial goal	Market Watch
08:49	Roivant Sciences' lupus drug fails to reduce symptoms in mid-stage study	Reuters
Monday, 13 November 2023
08:13	Roivant cash-flush after $7.15B Telavant sale to Roche as it reports mixed 3Q	Proactive Investors
Monday, 30 October 2023
17:30	Roivant to Report Financial Results for the Second Quarter Ended September 30, 2023, and Provide Business Update on Monday, November 13, 2023	GlobeNewsWire
Tuesday, 24 October 2023
09:25	Roivant Sciences: Risk-Transforming Deal Met With Crickets	Seeking Alpha
08:45	It's Hard to Be a Biotech Bull in This Market, but This Stock Is a Buy	The Motley Fool
Monday, 23 October 2023
15:25	Roivant Sciences Sells Joint Venture With Pfizer to Roche for $7.1 Billion	Investopedia
08:36	Roivant, Pfizer shares rise as Roche agrees to buy immunology company for $7.1 billion	Market Watch
07:00	Morgan Stanley's Wilson: Next rally attempt will fail as investors are punishing earnings reports.	Market Watch
Sunday, 1 October 2023
08:30	3 No-Brainer Growth Stocks to Buy in October	The Motley Fool
Wednesday, 27 September 2023
06:01	Roivant Sciences Ltd. (ROIV) Moves 21.6% Higher: Will This Strength Last?	Zacks Investment Research
Tuesday, 26 September 2023
16:59	Roivant stock could go higher on monetization potential of ‘blockbuster' assets	Proactive Investors
09:28	Immunovant and Roivant jump as new drug shapes up to become blockbuster	Proactive Investors
09:10	These 2 Biotech Stocks Are Bucking a Down Market Tuesday	The Motley Fool

Ideas & Opinions

Seeking Alpha 15 Aug 2025

Roivant Sciences: Vant Model And IMVT-1402 Create A 2025 Catalyst Stack
Seeking Alpha 23 Apr 2025

Roivant Sciences: Primed For Growth With A De-Risked Pipeline
Seeking Alpha 19 Jan 2025

Top 4 Immunology Stocks Poised For Growth In 2025
Seeking Alpha 27 Dec 2024

Duvakitug And Teva's Growth: A Game Changer In Pharma
Seeking Alpha 20 Dec 2024

Rethinking Stock Market Trump Trades
Seeking Alpha 7 Jun 2024

The 'Undercovered' Dozen From June 1-6
Seeking Alpha 2 Jun 2024

Roivant Sciences: Executing On Huge Buyback Program With More To Come
Seeking Alpha 7 Jan 2024

Roivant Sciences: Why Its 'Vant' Biotech Model Is A Buy
Seeking Alpha 24 Oct 2023

Roivant Sciences: Risk-Transforming Deal Met With Crickets
Seeking Alpha 14 Sep 2023

Sifting The World Day One

Frequently Asked Questions (FAQ)

What's the price of Roivant Sciences Ltd. stock today?

One share of Roivant Sciences Ltd. stock can currently be purchased for approximately $11.9.
When is Roivant Sciences Ltd.'s next earnings date?

Unfortunately, Roivant Sciences Ltd.'s (ROIV) next earnings date is currently unknown.
Does Roivant Sciences Ltd. pay dividends?

No, Roivant Sciences Ltd. does not pay dividends.
How much money does Roivant Sciences Ltd. make?

Roivant Sciences Ltd. has a market capitalization of 8.63B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 125.73% to 124.8M US dollars.
What is Roivant Sciences Ltd.'s stock symbol?

Roivant Sciences Ltd. is traded on the NASDAQ under the ticker symbol "ROIV".
What is Roivant Sciences Ltd.'s primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Roivant Sciences Ltd.?

Shares of Roivant Sciences Ltd. can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Roivant Sciences Ltd.'s key executives?
Roivant Sciences Ltd.'s management team includes the following people:
- Dr. Eric Venker M.D., Pharm.D. Pres & Chief Operating Officer(age: 38, pay: $813,550)
- Mr. Matthew Gline Chief Executive Officer & Director(age: 41, pay: $813,550)
- Mr. Vivek Ramaswamy Founder & Executive Chairman(age: 40, pay: $511,800)
Is Roivant Sciences Ltd. founder-led company?

Yes, Roivant Sciences Ltd. is a company led by its founder Mr. Vivek Ramaswamy.
How many employees does Roivant Sciences Ltd. have?

As Jul 2024, Roivant Sciences Ltd. employs 908 workers, which is 0% more then previous month and 0% more then previous quarter.
When Roivant Sciences Ltd. went public?

Roivant Sciences Ltd. is publicly traded company for more then 4 years since IPO on 8 Dec 2020.
What is Roivant Sciences Ltd.'s official website?

The official website for Roivant Sciences Ltd. is roivant.com.
How can i contact Roivant Sciences Ltd.?

Roivant Sciences Ltd. can be reached via phone at +44 20 7400 3347.
What is Roivant Sciences Ltd. stock forecast & price target?

Based on 3 Wall Street analysts` predicted price targets for Roivant Sciences Ltd. in the last 12 months, the avarage price target is $15.5. The average price target represents a 30.25% change from the last price of $11.9.

Roivant Sciences Ltd.

roivant.com

Exchange:

NASDAQ

Full time employees:

908

Industry:

Biotechnology

Sector:

Healthcare

Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.

+44 20 7400 3347

11-12 St. James's Square
London, SW1Y 4LB

CIK: 0001635088
ISIN: BMG762791017
CUSIP: G76279101